In the News March 30, 2017

The Pink Sheet | Off-Label Opioid Promotion: US FDA 'Does Not Object' To Intranasal Deterrence Data, Egalet Says

Marc Scheineson comments on the U.S. Food and Drug Administration’s approval of promotional materials highlighting a drug’s novel and generic abuse-deterrent formulation.
Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.